Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with several representatives of pharmaceutical distribution companies, as part of the Authority’s ongoing efforts to ensure the effective implementation of regulatory decisions, protect public health, and maintain the stability and safety of the Egyptian pharmaceutical market.

The meeting discussed the executive mechanisms for the withdrawal of expired pharmaceutical products from the local market and reviewed mechanisms for the safe disposal of these products in accordance with approved controls and standards.

Dr. Al-Ghamrawy emphasized that the withdrawal of expired pharmaceutical products is a top priority for the EDA, as it represents one of the key pillars for ensuring the quality and safety of pharmaceutical products available in the Egyptian market. He emphasized that the Authority continues to adhere to the highest standards of pharmaceutical supervision and good regulatory practices, in accordance with international norms.

He reaffirmed that the EDA will not hesitate to take any measures necessary to safeguard the health of Egyptian citizens and preserve the stability of the national pharmaceutical market. He emphasized that the cooperation and integration with distribution companies reflect a shared commitment to protecting public health and enhancing the efficiency of the pharmaceutical supply system.

Representatives of the pharmaceutical distribution companies expressed their appreciation for the supervisory and regulatory role of the Egyptian Drug Authority, confirming their full compliance with the EDA’s requirements to ensure the safe and organized implementation of the withdrawal process. They also emphasized their commitment to maintaining the efficiency of supply chains and ensuring the continued availability of safe and effective pharmaceutical products in the Egyptian market.

The meeting was attended on behalf of the Egyptian Drug Authority by:

· Dr. Tamer El-Hossieny, Vice Chairman of the Egyptian Drug Authority

· Dr. Amany Gawdat, Associate to the EDA Chairman and Supervisor of the Central Administration of the Chairman’s Office

· Dr. Osama Hatem, Associate to the EDA Chairman and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access

· Dr. Amira Mahjoub, Head of the Central Administration for Inspection of Pharmaceutical Establishments

· Dr. Hossam Abdallah, Associate to the EDA Chairman and General Manager of the General Administration for Market Support and Business Continuity

From the distribution sector:

· Dr. Mahmoud Abdel-Gawad, Chairman of the Board, Ibn Sina Pharma

· Dr. Mohamed Gazarine, Chairman of the Board, Pharma Overseas

· Dr. William Mahany, Chairman of the Board, Ramco Pharma

· Dr. Walid Saada, Chief Executive Officer of Supply Chains, Egyptian Company for Drug Trade

· Dr. Ramez Mahany, Vice Chairman of the Board, Ramco Pharma

This comes within the framework of the Authority's keenness for continuous coordination with all relevant stakeholders and distribution companies, and the periodic follow-up of the implementation process. This approach underscores the State’s commitment to protecting public health and supporting the national pharmaceutical industry.